Falcon Point Capital buys $19,146,667 stake in AMAG Pharmaceuticals (AMAG)

AMAG Pharmaceuticals (AMAG) : Falcon Point Capital scooped up 330,691 additional shares in AMAG Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 711,772 shares of AMAG Pharmaceuticals which is valued at $19,146,667.AMAG Pharmaceuticals makes up approximately 3.21% of Falcon Point Capital’s portfolio.

Other Hedge Funds, Including , Healthinvest Partners Ab reduced its stake in AMAG by selling 69,000 shares or 9.32% in the most recent quarter. The Hedge Fund company now holds 671,585 shares of AMAG which is valued at $18,065,637. AMAG Pharmaceuticals makes up approx 7.92% of Healthinvest Partners Ab’s portfolio. Huntington National Bank sold out all of its stake in AMAG during the most recent quarter. The investment firm sold 119 shares of AMAG which is valued $3,201. Ls Investment Advisors sold out all of its stake in AMAG during the most recent quarter. The investment firm sold 1,300 shares of AMAG which is valued $33,631.Capstone Asset Management Co boosted its stake in AMAG in the latest quarter, The investment management firm added 530 additional shares and now holds a total of 10,876 shares of AMAG Pharmaceuticals which is valued at $273,423. AMAG Pharmaceuticals makes up approx 0.01% of Capstone Asset Management Co’s portfolio.

AMAG Pharmaceuticals closed down -0.06 points or -0.23% at $26.53 with 3,72,430 shares getting traded on Friday. Post opening the session at $26.68, the shares hit an intraday low of $26.16 and an intraday high of $26.86 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, AMAG Pharmaceuticals reported $0.94 EPS for the quarter, missing the analyst consensus estimate by $ -0.13 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $1.07. The company had revenue of $117.90 million for the quarter, compared to analysts expectations of $124.59 million. The company’s revenue was up 41.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.17 EPS.

Many Wall Street Analysts have commented on AMAG Pharmaceuticals. Shares were Reiterated by Deutsche Bank on May 9, 2016 to “Hold” and Lowered the Price Target to $ 35 from a previous price target of $42 .AMAG Pharmaceuticals was Downgraded by Raymond James to ” Mkt Perform” on May 4, 2016.

AMAG Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on maternal health anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection) Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers such as those caused by oral surgery or ill-fitting dentures or braces.

Leave a Reply

AMAG Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on AMAG Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.